ABOS
Price
$2.99
Change
+$0.04 (+1.36%)
Updated
Nov 5, 04:45 PM (EDT)
6 days until earnings call
GBIO
Price
$2.18
Change
+$0.02 (+0.93%)
Updated
Nov 5, 04:00 PM (EDT)
2 days until earnings call
Ad is loading...

ABOS vs GBIO

Header iconABOS vs GBIO Comparison
Open Charts ABOS vs GBIOBanner chart's image
Acumen Pharmaceuticals
Price$2.99
Change+$0.04 (+1.36%)
Volume$100
CapitalizationN/A
Generation Bio
Price$2.18
Change+$0.02 (+0.93%)
Volume$17.79K
CapitalizationN/A
View a ticker or compare two or three
ABOS vs GBIO Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ABOS vs. GBIO commentary
Nov 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a StrongBuy and GBIO is a Buy.

COMPARISON
Comparison
Nov 05, 2024
Stock price -- (ABOS: $2.95 vs. GBIO: $2.17)
Brand notoriety: ABOS and GBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 101% vs. GBIO: 104%
Market capitalization -- ABOS: $177.24M vs. GBIO: $144.83M
ABOS [@Biotechnology] is valued at $177.24M. GBIO’s [@Biotechnology] market capitalization is $144.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileGBIO’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • GBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, ABOS is a better buy in the long-term than GBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 5 TA indicator(s) are bullish while GBIO’s TA Score has 2 bullish TA indicator(s).

  • ABOS’s TA Score: 5 bullish, 4 bearish.
  • GBIO’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than GBIO.

Price Growth

ABOS (@Biotechnology) experienced а +2.08% price change this week, while GBIO (@Biotechnology) price change was -7.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +14.28%, and the average quarterly price growth was +9.89%.

Reported Earning Dates

ABOS is expected to report earnings on Mar 31, 2025.

GBIO is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABOS($177M) has a higher market cap than GBIO($145M). GBIO YTD gains are higher at: 31.515 vs. ABOS (-23.177). ABOS has higher annual earnings (EBITDA): -62.11M vs. GBIO (-107.1M). ABOS has more cash in the bank: 260M vs. GBIO (217M). ABOS has less debt than GBIO: ABOS (28.2M) vs GBIO (94M). GBIO has higher revenues than ABOS: GBIO (13.2M) vs ABOS (0).
ABOSGBIOABOS / GBIO
Capitalization177M145M122%
EBITDA-62.11M-107.1M58%
Gain YTD-23.17731.515-74%
P/E RatioN/AN/A-
Revenue013.2M-
Total Cash260M217M120%
Total Debt28.2M94M30%
TECHNICAL ANALYSIS
Technical Analysis
ABOSGBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSEIX12.770.06
+0.47%
Hartford Small Cap Value I
RPBAX27.780.03
+0.11%
T. Rowe Price Balanced
PPQJX7.85N/A
N/A
Principal MidCap Growth III J
MLPIX112.90N/A
N/A
ProFunds Mid Cap Value Inv
SCGVX30.03-0.07
-0.23%
Sands Capital Global Growth Inv

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with ABCL. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+3.69%
ABCL - ABOS
52%
Loosely correlated
+5.49%
GBIO - ABOS
49%
Loosely correlated
-1.81%
MGTX - ABOS
48%
Loosely correlated
+2.75%
INZY - ABOS
47%
Loosely correlated
+1.38%
NTLA - ABOS
47%
Loosely correlated
+2.30%
More

GBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, GBIO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GBIO jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GBIO
1D Price
Change %
GBIO100%
-1.81%
EDIT - GBIO
49%
Loosely correlated
-1.03%
TECH - GBIO
47%
Loosely correlated
+0.78%
INZY - GBIO
47%
Loosely correlated
+1.38%
BEAM - GBIO
47%
Loosely correlated
+6.24%
NTLA - GBIO
46%
Loosely correlated
+2.30%
More